News and Trends 4 Jan 2023 Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to MET-X, the company’s broad spectrum metallo-beta-lactamase (MBL) inhibitor. Infex… January 4, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Apr 2024 5 RNA editing companies you should know about …rare and common diseases. It is currently working on advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well… April 18, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 8 Feb 2017 The First Stroke Drug in Decades? French Biotech gets closer to the Clinic …Medicine & Healthcare products Regulatory Agency (MHRA) received in January. Acticor’s candidate, ACT017, is a humanized antibody fragment (Fab) that inhibits the activity of platelet glycoprotein VI (GPVI). This strategy… February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2020 Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese Astellas Pharma to complete phase I trials of candidate off-the-shelf T-cell therapies for cancer including… January 15, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 Swedish Biotech Can Now Fast-Track its Metabolic Disorder Drug …addition, the company’s candidate has received Fast Track status from the FDA, which will help the candidate move into the clinic in 2018. Sanfilippo A syndrome is a life-threatening inherited… January 23, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 12 Feb 2024 RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing? …its RNA editing candidate, WVE-006. This was accepted, and dosing for that trial has now begun in the U.K., marking the first time an RNA editing candidate has reached the… February 12, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Nov 2022 Six biotech stocks trading below cash right now …result, Atea plans to test its lead candidate antiviral in a phase 3 trial by the end of 2022. The trial will recruit at least 1,500 high-risk, non-hospitalized patients with… November 16, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors …completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, the candidate reduced virus shedding,… January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2025 The biotech job market in 2025: Still in survival mode? …of remote biotech jobs. During the pandemic and in its immediate aftermath, remote roles helped decentralize the job market. But that trend has sharply reversed. Employers are now favoring candidates… April 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2024 Six exosome therapy companies driving development in the field …their candidates through the clinic. In this article, we take a look at six of the companies leading the way in the exosome therapy field. Table of contents Aegle Therapeutics … November 12, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Dec 2023 Nine biotech companies to watch in 2024 …noteworthy entry into the clinical-stage biopharmaceutical sector. At the heart of Aiolos Bio’s mission is AIO-001, a humanized anti-TSLP monoclonal antibody, developed as a treatment for moderate-to-severe asthma. This antibody… December 19, 2023 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight …Before its IPO, it attracted big-time investors like Medicxi and Sofinnova Partners, some of the top European biotech investors. The biotech has 3 different candidates at the clinical stage for… May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email